Northwest Biotherapeutics (NWBO) Capital Expenditures (2010 - 2026)

Northwest Biotherapeutics' Capital Expenditures history runs 16 years deep, the most recent figure standing at $129000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 38.71% year-over-year to $129000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 77.42% YoY), while the FY2025 annual figure was $1.5 million, up 48.32% from the prior year.
• Capital Expenditures for Q1 2026 stood at $129000.0, down from $905000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $2.2 million in Q4 2022, with the low at $58000.0 in Q1 2022.
• The 5-year median for Capital Expenditures is $304000.0 (2025), against an average of $528588.2.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 89.74% in 2022, then jumped 2198.28% in 2023.
• Northwest Biotherapeutics' Capital Expenditures stood at $2.2 million in 2022, then tumbled by 80.65% to $418000.0 in 2023, then sank by 81.34% to $78000.0 in 2024, then jumped by 1060.26% to $905000.0 in 2025, then slumped by 85.75% to $129000.0 in 2026.
• Business Quant data shows NWBO's Capital Expenditures at $129000.0 in Q1 2026, $905000.0 in Q4 2025, and $202000.0 in Q3 2025.